LGND NASDAQ
Ligand Pharmaceuticals Incorporated
1W: +0.5%
1M: +5.6%
3M: -5.5%
YTD: +59.4%
1Y: +69.2%
3Y: +392.9%
5Y: +248.9%
$302.96
+0.22 (+0.07%)
Weekly Expected Move ±4.1%
$278
$290
$303
$315
$328
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
18 relationships0
As Filer
counterparties named
18
As Counterparty
mentioned by others
2022-03-24
Earliest Filing
2026-03-31
Latest Filing
Mentioned As Counterparty
18 mentionsOther companies that named LGND in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| LONA LeonaBio, Inc. | partner | Counterparty to the Amended and Restated License Agreement with Sermonix | 2026-03-31 | View |
| AGEN AGENUS INC | partner | Entered into an amendment and release agreement regarding liens and warrant exercise price modification. | 2026-01-08 | View |
| LONA Athira Pharma, Inc. | partner | Licensee and counterparty in lasofoxifene license agreement | 2025-12-18 | View |
| LONA Athira Pharma, Inc. | partner | Licensee and counterparty in lasofoxifene license agreement | 2025-12-18 | View |
| PTHS Pelthos Therapeutics Inc. | investor | Investor in convertible note financing and collateral agent | 2025-11-07 | View |
| ELUT ELUTIA INC. | partner | Counterparty to royalty agreement amendment and asset sale | 2025-10-07 | View |
| PTHS Pelthos Therapeutics Inc. | partner | Parent of LNHC and partner in the merger and licensing agreements. | 2025-09-16 | View |
| OBIO Orchestra BioMed Holdings, Inc. | investor | PIPE investor and warrant recipient in private placement | 2025-08-04 | View |
| OBIO Orchestra BioMed Holdings, Inc. | investor | Purchased revenue participation rights and shares in a private placement. | 2025-07-31 | View |
| PTHS Pelthos Therapeutics Inc. | partner | Parent company of LNHC and PIPE investor in the merger and financing | 2025-07-02 | View |
| ELUT ELUTIA INC. | partner | Counterparty to royalty agreement amendment where Elutia issued shares to satisfy outstanding royalty obligations. | 2025-05-08 | View |
| PTHS Channel Therapeutics Corp | partner | Parent company of LNHC and participant in the PIPE Financing. | 2025-04-17 | View |
| AGEN AGENUS INC | target | Acquired 31.875% of milestone payments, 18.75% of royalties, and a synthetic royalty on net sales of botensilimab and ba | 2024-05-30 | View |
| AGEN AGENUS INC | target | Acquired 31.875% of milestone payments, 18.75% of royalties, and a synthetic royalty on net sales of botensilimab and ba | 2024-05-07 | View |
| ELUT ELUTIA INC. | partner | Elutia Med entered into an Amendment to a Royalty Agreement with Ligand Pharmaceuticals Incorporated. | 2024-01-12 | View |
| OVID Ovid Therapeutics Inc. | target | Acquired a 13% interest in soticlestat royalties and milestones from Ovid Therapeutics for $30 million. | 2023-10-18 | View |
| OABIW OmniAb, Inc. | partner | Former parent company of Legacy OmniAb that entered into a business combination and separation agreement. | 2022-11-07 | View |
| OABIW Avista Public Acquisition Corp. II | partner | Parent company of OmniAb entering a Reverse Morris Trust transaction to spin off its antibody discovery business. | 2022-03-24 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR